Search Results

Editorial

Lilly vs. Novo: The ‘He Said, She Said’ Row About Catalent’s GLP-1 Work

With Novo Holdings’ $16.5 billion buyout of Catalent being reviewed by regulators, what work the contract drug manufacturer may or may not be performing for Eli Lilly remains a point of contention.

November 8, 2024

·

4 min read

·

Greg Slabodkin

pharmacy medicine capsule pill in production line at medical factory

Deals

Amid Novo Buy, Catalent Offloads New Jersey Facility to Ardena

European CDMO Ardena will buy Catalent’s oral solids manufacturing facility in Somerset, N.J.

October 14, 2024

·

1 min read

·

Annalee Armstrong

Trendy halftone collage. Concept of contracting, negotiation, contracting, favorable terms. Trendy modern retro illustration on business theme. Concept of teamwork. Vector illustration

Mergers & acquisitions

Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.

December 16, 2024

·

2 min read

·

Tristan Manalac

Editorial

Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’

The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.

October 24, 2024

·

6 min read

·

Jef Akst

Factory plant conveyor line production development industrial interior design flat background concept illustration

Manufacturing

Novo-Catalent Deal Represents ‘Defining Moment’ for CDMO Sector

Novo Holdings’ acquisition of Catalent has ignited concerns from industry stakeholders, who fear that the consolidation could limit competition, but there is also the possibility that the deal could represent an opportunity for smaller-scale CDMOs to find new partners.

November 13, 2024

·

4 min read

·

Ben Hargreaves

Close-up of medical ampoule production line/iStock

Earnings

Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, 2024. The miss comes amid growing opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent.

November 6, 2024

·

3 min read

·

Tristan Manalac

Press Releases

Novo Holdings Completes Acquisition of Catalent

December 18, 2024

·

4 min read

Pictured: Entrance to the FTC's office in Washington, DC

Editorial

Pressure Mounts on Novo’s $16.5B Catalent Buy Amid FTC Review

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could increase Novo’s dominance over the hot GLP-1 market, reducing competition and increasing prices.

October 11, 2024

·

3 min read

·

Greg Slabodkin

Podcast

Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More

J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona comes at a bad time for the company; Sen. Warren calls for scrutiny of Novo’s purchase of Catalent; and other news.

October 16, 2024

·

1 min read

·

Heather McKenzie

Deals

Catalent Stockholders Approve Transaction with Novo Holdings

Catalent, Inc. announced that, at its Special Meeting of Stockholders held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S will acquire all outstanding shares of Catalent for $63.50 per share in cash.

May 29, 2024

·

7 min read